Clinical Report: Surgical Sequencing in Esophageal Cancer
Overview
A phase 3 trial found no significant survival differences between neoadjuvant chemoradiotherapy followed by surgery and surgery followed by adjuvant therapy in locally advanced esophageal squamous cell carcinoma. However, patients achieving a pathologic complete response after neoadjuvant treatment had significantly improved survival outcomes.
Background
Esophageal cancer is a major global health concern, being the seventh most diagnosed cancer and the sixth leading cause of cancer mortality. Treatment strategies, including surgical sequencing, are critical for improving survival rates in patients with locally advanced esophageal squamous cell carcinoma. Understanding the effectiveness of neoadjuvant versus adjuvant therapies can guide clinical decision-making.
Data Highlights
| Outcome | NCRT Group | Adjuvant Therapy Group |
|---|---|---|
| 5-year overall survival | 59% | 59% |
| 5-year disease-free survival | Exceeds 50% | Exceeds 50% |
| Pathologic complete response (pCR) | 34 (29%) | N/A |
| Pathologic stage I post-surgery | More than 50% | Most classified as stage III |
Key Findings
- No significant difference in long-term survival between NCRT followed by surgery and surgery followed by adjuvant therapy.
- 5-year overall survival was 59% in both treatment groups.
- Patients achieving pCR after NCRT had a 5-year overall survival of 77%.
- More than half of NCRT patients were classified as pathologic stage I post-surgery, compared to most adjuvant therapy patients classified as stage III.
- Rates of lymph node involvement and vascular invasion were lower in the NCRT group.
- Safety profiles were comparable, though NCRT patients experienced more hematologic and gastrointestinal toxic effects.
Clinical Implications
The findings suggest that both neoadjuvant chemoradiotherapy and surgery followed by adjuvant therapy are viable options for treating locally advanced esophageal squamous cell carcinoma. Clinicians should consider the likelihood of achieving a pathologic complete response when determining treatment strategies for individual patients.
Conclusion
The study highlights the importance of personalized treatment approaches in esophageal cancer, emphasizing that neoadjuvant therapy may not be necessary for all patients. Further research is needed to refine treatment protocols based on individual patient responses.
Related Resources & Content
- Surgical Endoscopy, 2023 -- Reverse Sequence Esophagectomy: An Emerging Surgical Option for Esophageal Cancer Treatment
- Updates in Surgery, 2025 -- Outcomes Comparison in Esophageal Cancer Patients Undergoing Single-Port Versus Four-Port Thoracoscopic Esophagectomy: Insights from a Single-Center Study
- Surgical Endoscopy, 2026 -- Gastric ischemic conditioning before esophagectomy: contemporary practices and insights from an international survey
- The ASCO Post, 2014 -- Customizing Surveillance Strategy in Patients With Esophageal Adenocarcinoma
- Esophageal Cancer Treatment (PDQ®) - NCI
- RePub, Erasmus University Repository -- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial
- Esophageal Cancer Treatment (PDQ®) - NCI
- RePub, Erasmus University Repository: Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
